论文部分内容阅读
目的:探讨唑来膦酸联合硫酸吗啡缓释治疗多发骨转移性疼痛的疗效及耐受性。方法:选择恶性肿瘤伴多发性骨转移、初始为重度疼痛、经硫酸吗啡缓释片治疗14天以上疼痛未达到中度以上缓解者。共入组患者52例,给予唑来膦酸联合硫酸吗啡缓释片治疗,比较联合治疗前后疗效及不良反应。结果:联合治疗前疼痛评分为7.3,联合治疗后降至1.4(P<0.001),联合治疗总有效率76.9%,生活质量良好者比例由9.6%增至71.2%(P<0.001)。8例出现发热,对症处理后体温当日降至正常。结论:唑来膦酸联合硫酸吗啡缓释片治疗多发骨转移性顽固性疼痛,明显提高患者生活质量,副反应未见增加,疗效及耐受性好。
Objective: To investigate the efficacy and tolerability of zoledronic acid combined with sustained release morphine sulfate in the treatment of multiple bone metastatic pain. Methods: Select malignant tumor with multiple bone metastases, the initial severe pain, morphine sulfate sustained-release tablets for more than 14 days did not reach more than moderate pain relief. A total of 52 patients were enrolled and treated with zoledronic acid plus morphine sulfate sustained-release tablets. The curative effect and adverse reactions were compared before and after treatment. Results: The pain score before combination therapy was 7.3 and decreased to 1.4 after combination therapy (P <0.001). The total effective rate of combination therapy was 76.9% and the proportion of good quality of life increased from 9.6% to 71.2% (P <0.001). 8 cases of fever, symptomatic treatment after the body temperature dropped to normal. Conclusion: Zoledronic acid combined with morphine sulfate sustained-release tablets in the treatment of multiple bone metastatic refractory pain, significantly improve the quality of life of patients, no increase in side effects, efficacy and tolerability.